ERBB2 and breast carcinoma: Similar to what was seen upon siRNA-mediated Vps34 knockdown, Vps34 inhibition using SAR405 had only modest anti-proliferative effects as a single agent in HER2-amplified breast cancer cells (Fig. 5a), and no impact on phosphorylation of Akt (Fig. 5b).